Title
Exploring Adolescent Patient Experiences in Receiving Blinatumomab

Description
Exploring Adolescent Patient Experiences in Receiving Blinatumomab

Objective
Primary Objective:
To explore adolescent patient experiences and perspectives of receiving blinatumomab for treatment of acute lymphoblastic leukemia at the University of Wisconsin American Family Children s Hospital.

Treatment 10 adolescent patients (ages 10-19) will be purposively sampled from American Family Children’s Hospital in Madison, Wisconsin.

Key Eligibility Eligible participants must (a) be a patient between the ages of 10 to 19 with a diagnosis of acute lymphoblastic leukemia who is either currently receiving blinatumomab or received blinatumomab within the past one year, (b) received at least two weeks of the infusion, (c) be able to provide parental consent if less than age 18 as well as assent if less than age 18, and (d) be English speaking. The ages of 10 to 19 were selected due to ages 10 and above being considered developmentally appropriate to answer questions for the interview. We also routinely see patients up to age 19 at our center.

Applicable Disease Sites
Leukemia

Participating Institutions
UW Health University Hospital